本文選題：惡性膠質(zhì)瘤 + 信號通路��； 參考：《中華腫瘤防治雜志》2017年05期

【摘要】：目的惡性膠質(zhì)瘤是一種最常見的原發(fā)惡性腦腫瘤,是癌癥治療中最具挑戰(zhàn)性疾病之一。因?yàn)槭中g(shù)切除后腫瘤易復(fù)發(fā)和治療抵抗性,患者預(yù)后普遍較差。膠質(zhì)瘤的分子靶向治療正逐漸引起廣泛關(guān)注。本研究總結(jié)惡性膠質(zhì)瘤發(fā)病相關(guān)的分子病理改變和靶向藥物的臨床應(yīng)用與研究進(jìn)展。方法采用PubMed文獻(xiàn)檢索系統(tǒng),以"惡性膠質(zhì)瘤"和"分子靶向治療"為關(guān)鍵詞,檢索2007-01-01-2015-12-31的相關(guān)文獻(xiàn)。納入標(biāo)準(zhǔn):(1)與惡性膠質(zhì)瘤分子靶向通路相關(guān)的文獻(xiàn);(2)與惡性膠質(zhì)瘤抗血管生成治療相關(guān)的文獻(xiàn);(3)與惡性膠質(zhì)瘤分子靶向藥物的Ⅰ期及Ⅱ期臨床研究相關(guān)的文獻(xiàn);(4)與惡性膠質(zhì)瘤分子靶向耐藥相關(guān)的文獻(xiàn)。根據(jù)納入標(biāo)準(zhǔn)分析文獻(xiàn)43篇。結(jié)果膠質(zhì)瘤靶向治療方向主要集中在RTK/RAS/PI3K通路、促血管生成通路和一些其他重要的細(xì)胞內(nèi)信號轉(zhuǎn)導(dǎo)通路。然而,一些因素如信號通路之間的串?dāng)_、瘤內(nèi)異質(zhì)性和膠質(zhì)瘤干細(xì)胞的治療抵抗性限制了單一藥物的活性。各種分子靶向藥物單藥治療未能表現(xiàn)出更好的生存獲益,還需與其他治療方法聯(lián)合應(yīng)用。目前對于惡性膠質(zhì)瘤患者多靶點(diǎn)激酶抑制劑治療的研究還處于起始階段。結(jié)論分子靶向藥物在惡性膠質(zhì)瘤的治療中具有重要臨床意義和應(yīng)用潛力,但由于膠質(zhì)瘤的復(fù)雜的分子生物學(xué)特性,分子靶向治療面臨諸多挑戰(zhàn),還需進(jìn)一步探索與研究。
[Abstract]:Objective malignant glioma is one of the most common primary malignant brain tumors and one of the most challenging diseases in cancer treatment. The prognosis of the patients is generally poor because of the recurrence and resistance to treatment after surgical resection. Molecular targeting therapy of glioma is gradually attracting wide attention. This study summarized the molecular pathological changes related to the pathogenesis of malignant gliomas and the clinical application and research progress of targeted drugs. Methods PubMed literature retrieval system was used to search the literature related to "malignant glioma" and "molecular targeted therapy" for 2007-01-2015-12-31. Inclusion criteria: (1) literature related to molecular targeting pathway for malignant gliomas; (2) literature related to antiangiogenic therapy for malignant gliomas; (3) literature related to phase I and phase II clinical studies of molecular targeting drugs for malignant gliomas; (4) Literature related to molecular targeting drug resistance in malignant gliomas. According to the inclusion criteria, 43 articles were analyzed. Results the targeted therapy of glioma mainly focused on RTK / RAS-PI3K pathway, angiogenesis pathway and some other important intracellular signal transduction pathways. However, factors such as crosstalk between signaling pathways, intratumoral heterogeneity and therapeutic resistance to glioma stem cells limit the activity of a single drug. All kinds of molecular targeted drug monotherapy can not show better survival benefit and need to be used in combination with other treatment methods. The study of multi-target kinase inhibitors in malignant gliomas is still in its infancy. Conclusion Molecular targeting drugs have important clinical significance and potential application in the treatment of malignant gliomas. However, due to the complex molecular biological characteristics of gliomas, molecular targeted therapy faces many challenges, which need to be further explored and studied.
【作者單位】： 青島大學(xué)附屬醫(yī)院放療科;
【分類號】：R739.41

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 Steinbach J.P;Blaicher H.-P;Herrlinger U;郭俊;;存活5年以上惡性膠質(zhì)瘤患者的狀況[J];世界核心醫(yī)學(xué)期刊文摘(神經(jīng)病學(xué)分冊);2006年11期

2 陳海燕;白永瑞;;惡性膠質(zhì)瘤的綜合治療現(xiàn)狀[J];臨床腫瘤學(xué)雜志;2010年08期

3 浦佩玉;惡性膠質(zhì)瘤的治療進(jìn)展[J];醫(yī)師進(jìn)修雜志;1995年11期

4 楊海城,蘇君,張學(xué)新,肖宏;幕上惡性膠質(zhì)瘤腦脊液播散2例[J];黑龍江醫(yī)學(xué);2001年08期

5 許茂盛,李來友,陳星榮,喻迎星,馮曉源,沈天真;惡性膠質(zhì)瘤的二維氫質(zhì)子磁共振波譜研究[J];中國醫(yī)學(xué)計(jì)算機(jī)成像雜志;2002年05期

6 陳志剛,盧亦成,丁學(xué)華,朱誠;惡性膠質(zhì)瘤化療新進(jìn)展[J];中華神經(jīng)外科雜志;2003年01期

7 姜新雅,仇斌,李文政,王維;顱內(nèi)惡性膠質(zhì)瘤術(shù)后腦組織正常反應(yīng)與術(shù)后殘存的動態(tài)增強(qiáng)MRI鑒別[J];中國醫(yī)學(xué)影像技術(shù);2004年04期

8 陳海燕;白永瑞;;惡性膠質(zhì)瘤的放射治療進(jìn)展[J];中國神經(jīng)腫瘤雜志;2009年03期

9 李贊;晉雯;;惡性膠質(zhì)瘤發(fā)病機(jī)制及治療學(xué)的新進(jìn)展[J];海峽藥學(xué);2010年03期

10 呂磊;梁玉敏;高國一;潘耀華;包映暉;吳海波;丁圣豪;陳磊;江基堯;h侗疽擻，

本文編號：2106298